298197-04-3

Basic information

• Product Name: Fatostatin A
• Synonyms: Fatostatin A;4-[4-(4-Methylphenyl)-2-thiazolyl]-2-propylpyridine MonohydrobroMide;Fatostatin A HydrobroMide;2-(2-propylpyridin-4-yl)-4-p-tolylthiazole hydrobromide;25B11 hydrobromide;4-[4-(4-methylphenyl)-2-thiazolyl]-2-propylpyridine hydrobromide;Fatostatin hydrobromide;Fatostatin
• CAS NO: 298197-04-3
• Molecular Formula: BrH*C₁₈H₁₈N₂S
• Molecular Weight: 375.32586
• Product Categories: Aromatics, Heterocycles, Inhibitors, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 298197-04-3.mol

Chemical Properties

• Appearance: light yellow to yellow/
• Storage Temp.: 2-8°C
• Solubility: DMSO: ≥10mg/mL
• CAS DataBase Reference: Fatostatin A(CAS DataBase Reference)
• NIST Chemistry Reference: Fatostatin A(298197-04-3)
• EPA Substance Registry System: Fatostatin A(298197-04-3)

Safety Data

• Hazard Codes: Xn
• Statements: 22
• WGK Germany: 1
• Hazardous Substances Data: 298197-04-3(Hazardous Substances Data)

Usage

Uses

Used in Metabolic Disorders Treatment:
Fatostatin A is used as a therapeutic agent for the treatment and/or prevention of one or more metabolic disorders. It helps in reversing hyperglycemia in diabetic mice, making it a potential candidate for managing diabetes and related metabolic conditions.
Used in Anticancer Applications:
Fatostatin A is employed as an anti-cancer agent, demonstrating anti-tumor and antimitotic properties. It has been used to study its anti-cancer activity and effects on mitotic microtubule spindle, as well as its role in preventing SREBP cleavage-activating protein (SCAP)-mediated escort of sterol regulatory element-binding proteins (SREBPs).
Used in Cell Biology Research:
Fatostatin A is used as a research tool to study its effects on stomatal development and other cellular processes. Its cell permeable nature allows for easy incorporation into various experimental setups, facilitating the investigation of its mechanisms of action and potential applications in cell biology.

Biological Activity

fatostatin a is an inhibitor of sterol regulatory element binding protein (srebp), which can inhibit the activation of srebp-1 and srebp-2[1].fatostatin a (0.1-1 μm; 3 days) inhibits the androgen-independent proliferation of prostate cancer cell in a manner independent of the known igf1 signaling pathway. fatostatin a inhibits insulin-induced fat formation in 3t3-l1 cells[2].fatostatin a (30 mg/kg; 150 ml; i.p.; daily for 28 days) prevents obese ob/ob mice from increasing their weight, blood sugar, and liver fat accumulation, even if they do not control the food intake of mice[1].[1]. kamisuki s, et al. a small molecule that blocks fat synthesis by inhibiting the activation of srebp. chem biol. 2009, 16(8): 882-92.[2]. choi y, et al. identification of bioactive molecules by adipogenesis profiling of organic compounds. j biol chem. 2003, 278(9): 7320-4.

Biochem/physiol Actions

Fatostatin hydrobromide is an SREBP inhibitor. Fatostatin hydrobromide inhibits fat production and lowers glucose levels in mice by inhibiting SREBP (Sterol Regulatory Element Binding Proteins).

Upstream product

• 14222-60-7 prothionamide 
• 619-41-0 4-(bromoacetyl)toluene 

Relevant articles and documents

COMPOSITIONS AND METHODS FOR THE TREATMENT OF METABOLIC DISORDERS

The present invention relates to treatment and/or prevention of one or more metabolic disorders utilizing fatostatin A and/or a derivative and/or analog thereof. In other aspects, the compound for treatment and/or prevention of one or more metabolic disorders utilizes an A-B-C tripartite structure, wherein A, B, and C are identical or non-identical structures and are described in detail herein. In specific aspects, the metabolic disorder includes obesity or diabetes, for example.